Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Chronic Myeloid Leukemia
4.2.2 Advancement in Drug Development
4.2.3 Increasing Investments in Research and Development
4.3 Market Restraints
4.3.1 Side effects Associated with Chemotherapy
4.3.2 Stringent Regulations on Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Treatment Type
5.1.1 Targeted therapy
5.1.2 Chemotherapy
5.1.3 Biologic therapy
5.1.4 Other Treatment Types
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Co.
6.1.2 Novartis AG
6.1.3 Pfizer Inc.
6.1.4 Takeda Pharmaceutical Company Limited
6.1.5 Teva Pharmaceutical Industries Ltd.
6.1.6 Viatris Inc. (Mylan)
6.1.7 Merck & Co., Inc.
6.1.8 F. Hoffmann-La Roche Ltd.
6.1.9 Boehringer Ingelheim International GmbH
6.1.10 Sanofi
6.1.11 Cipla Inc. (Cipla USA Inc.)
6.1.12 Amneal Pharmaceuticals LLC
6.1.13 Accord Healthcare, Inc
6.1.14 Fresenius Kabi AG


7 MARKET OPPORTUNITIES AND FUTURE TRENDS